4:20 PM
Nov 30, 2017
 |  BC Extra  |  Clinical News

J&J begins Phase IIb trial of mosaic HIV vaccine

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill & Melinda Gates Foundation and NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

The mosaic approach is intended to address many of the different HIV subtypes found globally, unlike previous approaches that focus on viruses from specific geographical areas. The vaccine, Ad26.Mos4.HIV, incorporates immunogens created...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >